The cyclopentapeptide CXCR4 antagonist FC131 (cyclo(-Arg 1 -Arg 2 -2-Nal 3 -Gly 4 -D-Tyr 5 -), 2; 2-Nal = 3-(2-naphthyl)alanine) represents an excellent starting point for development of novel drug-like ligands with therapeutic potential in HIV, cancer, stem-cell mobilization, inflammation, and autoimmune diseases. While the structure-activity relationships for Arg 1 , Arg 2 , and Gly 4 are well established, less is 10 understood about the roles of the aromatic residues 2-Nal 3 and D-Tyr 5 . Here we report further structureactivity relationship studies of these two positions, which showed that (i) the distal aromatic ring of the 2-Nal 3 side chain is required in order to maintain high potency, and (ii) replacement of D-Tyr 5 with conformationally constrained analogues results in significantly reduced activity. However, a simplified analogue that contained Gly instead of D-Tyr 5 was only 13-fold less potent than 2, which means that the 15 D-Tyr 5 side chain is dispensable. These findings were rationalized based on molecular docking, and the collective structure-activity data for the cyclopentapeptides suggest that appropriately designed Arg 2 -2-Nal 3 dipeptidomimetics have potential as CXCR4 antagonists.
Introduction
By now, the role of the G protein-coupled C-X-C chemokine 20 receptor 4 (CXCR4) in HIV, cancer, stem-cell mobilization, inflammation, and autoimmune diseases is well established, 1 and several different antagonists for CXCR4 -both peptides and nonpeptides -have been described in the literature over the last two decades. 2 The prototype non-peptide antagonist plerixafor 25 (AMD3100), which is administered by subcutaneous injection, was approved for stem-cell mobilization in 2008 and is currently the only marketed CXCR4 antagonist. The molecular pharmacology of AMD3100 3, 4 and the structurally related nonpeptide antagonists AMD3465 5 and AMD11070 6 has been 30 extensively characterized. 7 The majority of the reported peptide antagonists has been developed by Fujii and co-workers, starting from the 18-mer synthetic polyphemusin II analogue T22. 8 Extensive structureactivity relationship (SAR) and downsizing studies first led to the 35 potent 14-mer antagonist T140 (1, Fig. 1 ), 9 and eventually to the discovery of the cyclopentapeptide FC131 (2, Fig. 1 ), 10 which we are currently using as lead compound for our ongoing efforts toward peptidomimetic CXCR4 antagonists. A 16-mer analogue of 1 that contains two additional C-terminal residues (CVX15, 3,
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Fig. 1) was recently reported by Wu et al. as the ligand in an Xray co-crystal structure of CXCR4. 11 Interestingly, the potent peptide antagonists 1-3 share an Arg 1 -Arg 2 -(n-Nal) 3 -Xaa 4 -L-/DTyr 5 pentapeptide motif ( Fig. 1 ), a notable difference being that 1 and 2 both contain 3-(2-naphthyl)alanine (2-Nal) in position 3 45 while 3 contains the isomeric 3-(1-naphthyl)alanine (1-Nal). pentapeptide motif is shown in bold, and the aromatic positions 3 and 5 are highlighted with grey background. Cit = citrulline; 1-Nal = 3-(1-naphthyl)alanine; 2-Nal = 3-(2-naphthyl)alanine.
Aromatic rings and charged groups in ligand side chains have consistently been found to play a special role in binding and activation of peptidergic GPCRs. 12 Several SAR studies of the cyclopentapeptide 2 ( Fig. 1 On this background, we have performed further SAR studies of the two aromatic positions in the lead cyclopentapeptide 2. Based on the nature of the already existing SAR data, two 25 different approaches were used: for position 3 a classical SAR study, and for position 5 the introduction of conformational rigidity/flexibility. Here we report the findings of these SAR studies, an interpretation of the data based on molecular docking, and the implications for design of novel peptidomimetic CXCR4 30 antagonists.
Results and discussion

Design and SAR for position 3
In addition to the Ala 3 analogue that was classified as inactive, result in good activity, 14 which could be expected based on the structural similarity with 2-Nal. In contrast, N-methylation (NMe-2-Nal 3 ) was shown to significantly reduce the antagonistic activity, 16 while introduction of a conformationally constrained Trp-derivative resulted in an inactive compound.
14 45 However, analogues with aromatic side chains that are significantly different from 2-Nal have not previously been reported for this position. For the SAR study in position 3, we therefore replaced 2-Nal with aromatic and aliphatic residues of different size and shape, giving a compound series that contained 50 small (4-6), medium (7) (8) (9) (10) , and large (11, 12) side chains (Fig.  2) . For reference purposes the known Ala 3 analogue 13 14 was also included. Our synthetic strategy for preparation of cyclopentapeptide ligands and the biological assay for determination of antagonistic potency have recently been 55 described.
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The analogues 4-13 were all significantly less potent than 2 (EC 50 = 0.40 µM) (Fig. 2) . The most potent compound was the isomeric 1-Nal 3 analogue 10 (EC 50 = 5.6 µM, 14-fold reduction in potency), and the only compounds with activity (EC 50 < 100 µM) 60 contained a medium-sized substituent (2 > 10 > 9, 8, 7). Thus, the present SAR data show that position 3 of the cyclopentapeptides is very sensitive toward substitutions, and that 2-Nal remains the best residue in this position. Interestingly, Fujii et al. have previously reported a SAR study in the corresponding position 3 of the parent 14-mer peptide antagonist 1 (Fig. 1) , 19 which showed that the Phe 3 analogue was 70 only 6-fold less active than the 2-Nal 3 analogue (1), and 7-fold more active than the 1-Nal 3 analogue. This is in contrast to the present findings, where the Phe 3 analogue 5 was inactive, meaning that the main contribution comes from the distal aromatic ring of 2-Nal 3 . Thus, the SAR trends obtained for the 75 larger peptide scaffold 1 cannot automatically be transferred to the cyclopentapeptide scaffold of 2. Moreover, the CXCR4 cocrystal peptide ligand 3 ( Fig. 1 ) contains 1-Nal 3 instead of 2-Nal 3 , while still being very potent (IC 50 = 0.6 nM). 11 Thus, the present SAR data indicates that the 2-Nal 3 side chain of 2 approaches its 80 subpocket in a different way than the corresponding side chain of the larger peptides 1 and 3.
Design and SAR for position 5
For position 5 (D-Tyr), a larger number of cyclopentapeptide analogues have been reported in the literature. 14, 16, 20, 21 The L- analogue resulted in a 6-fold reduction in affinity, 14 while introduction of a halogen on the phenyl ring led to further affinity reduction. 21 Similarly, replacement of the 4-hydroxyl group with a 4-amino or a 4-methoxy group resulted in 13-fold and 64-fold reduction in affinity, respectively. 14 Overall, the reported phenyl- 14 (Fig. 3) . 10 Compounds 19 and 20 failed to produce any antagonistic activity (EC 50 > 100 µM), while 21 was moderately active (EC 50 = 51 µM), which confirms that the backbone effects are partly responsible for the relatively low potency of 16-18. These findings are consistent with data for the N-methylated analogue
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(N-Me-D-Tyr 5 ), which resulted in a 32-fold reduction in activity compared to 2. 16 Realizing that introduction of conformational constraints in position 5 was counterproductive, we went in the opposite direction and prepared the Gly 5 analogue 22 (Fig. 3) . 
Rationalization of SAR for the two aromatic positions in terms of receptor binding
The sequence similarity between the 16-mer 3 and the cyclopentapeptide 2 ( Fig. 1) suggests that the binding mode for 2 30 can be inferred from the co-crystal structure of 3 and CXCR4 (PDB code 3OE0). 11 However, inspection of this structure shows that the distance between Arg 1 and Tyr 5 in the receptor-bound conformation of 3 is not compatible with head-to-tail cyclization, which is required for 2. This means that the position of some side 35 chains in 2 must be shifted relative to the corresponding side chains in 3. The crystal structure further shows that the aromatic side chains in positions 3 (1-Nal) and 5 (Tyr) of 3 are both located in hydrophobic regions around transmembrane helix (TMH) 5; 1-Nal 3 at the bottom of the pocket, and Tyr 5 higher up, 40 close to the extracellular loop between TMHs 4 and 5. In order to rationalize the present SAR data for the aromatic positions 3 and 5 in cyclopentapeptide ligands, compounds 2, 14, and 22 were docked to this X-ray structure using an optimized docking protocol as recently described. 15 Specifically, based on 45 preliminary site-directed mutagenesis studies that identified Asp171 in TMH4 as important for the activity of 2, 26 a H-bond constraint was placed on Asp171 to reduce the number of irrelevant poses. Moreover, Arg188 in extracellular loop 2 was temporarily mutated to alanine since the side chain partly 50 restricted access to the sub-pocket containing Asp171. their top scoring poses (data not shown); thus, they can be collectively represented by the binding mode for 2 (Fig. 4) . The 2-Nal 3 side chain is accommodated in a well-defined hydrophobic subpocket mainly composed of residues in TMH 5 (Fig. 4A) . The restrictions of this subpocket would explain the reduced potency (14) ; the 4-hydroxyl group of 2 forms an additional H-bond with Glu32 (Fig. 4B) , which would explain its higher activity. Still, the phenyl ring of 2 and 14 is located in a relatively open region and is partially solvent exposed (Fig. 4B) exposed. However, it should be noted that the Asp171-constraint used to generate these poses is based on preliminary site-directed mutagenesis data for 2, and that alternative binding modes have been suggested. 27 Thus, further experimental studies are needed to fully establish the binding mode for cyclopentapeptide CXCR4 25 antagonists.
Experimental General
All reagents and solvents were purchased and used as received. given in hertz (Hz) and the values are given in δ scale.
Chemistry
The target compounds 4-22 were synthesized as recently described for 2. 15 Briefly, the linear pentapeptide precursor was synthesized by standard Fmoc-based solid-phase peptide 50 synthesis using a preloaded Fmoc-Gly Novasyn TGT resin. After cleavage from the resin, the linear side chain protected pentapeptide was cyclized head-to-tail in dilute solution to give the side chain protected cyclopentapeptide. Following deprotection, the crude peptide was purified by preparative HPLC 55 and lyophilized to give the final products 4-22 as di(trifluoroacetate) salts. The identity of all final products was confirmed by HRMS and NMR, and all compounds were >95% pure as determined by analytical HPLC, see ESI.
Biology
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Computational studies
The cyclopentapeptide ligands 2, 14, and 22 were docked to the CXCR4 structure using Schrödinger's induced fit docking workflow 28 as recently described. 15 Briefly, the X-ray co-crystal structure of human CXCR4 and the 16-mer peptide antagonist 75 CVX15 (PDB code 3OE0) 11 was prepared for docking using the Protein Preparation Wizard workflow. 29 The three ligands were docked to this structure using our optimized protocol, 15 and the top 10 poses within an energy window of 30 kcal/mol were kept for each ligand. Visual inspection of the 30 generated poses 80 resulted in the identification of the common binding mode for 2, 14, and 22 that is discussed above.
Conclusions
The SAR data presented here clearly show that the naphthyl group in position 3 is more important for activity than the phenol 85 group in position 5 (13 vs 21), and that the distal aromatic ring of the 2-Nal 3 side chain is critical in order to maintain potency. 
